65,437 trials
Carcinoma, Hepatocellular
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 8.2; 8.1 Months
Binge-Eating Disorder
Primary: Change in Binge Eating Frequency — 6.4; 5.4 binge-eating episodes per month — p=.44
Diabetes Mellitus, Type 2
Primary: Change in EGP From Baseline to Post-oral Glucose Load. — -0.03; -0.18; 0.14; -0.08 mg/kg.min
Critical COVID-19 With Respiratory Failure · Acute Respiratory Distress Syndrome (ARDS) · Corona Virus Infection
Primary: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) — 72; 33 Participants
Xerostomia
Primary: Change in Oral Health Related Quality of Life (OHRQoL) — 10.2 score on a scale
Chronic Obstructive Pulmonary Disease
Primary: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 — 0.0480…
Atopic Dermatitis
Primary: Change in EASI Score From Baseline to Week 16 — -15.3; -3.5 score on a scale — p=0.003
Painful Diabetic Neuropathy
Primary: Percentage of Subjects With Adverse Events (AE) Reported Spontaneously by the Subject or Observed by the Investigator — 80.9 percentage of participants
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
Smoking, Cigarette
Primary: Proportion of Participants With Self-Reported 7-day Point Prevalence Abstinence From Cigarettes — 41; 33 Participants
Influenza
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain on Day 0 — 87.5704; 71.2385; 69.1840; 60.7941…
Posterior Blepharitis · Meibomian Gland Dysfunction
Primary: Adverse Events — 1; 1; 2; 0 adverse events
Dental Caries Class I · Dental Caries Class II
Primary: Clinical Acceptance Rate of Restoration at 1 Year After Replacement — 120; 119; 0; 1 Participants — p=< 0.0001
End-stage Renal Disease · Prevention of Thromboembolic Events · Hemodialysis
Primary: Cumulative Incidence Risk of the First Composite of Major Bleeding (MB) and Clinically-relevant Non-major Bleeding (CRNMB) Events as Assessed by Blinded Central…
Systemic Lupus Erythematosus (SLE)
Primary: Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24 — 37.3; 48.5; 54.8 percentage…